Articles By This Author

JPMorgan retains Market Perform, $203 target by KBW By Investing.com
- By aicren.com
- . May 16, 2024
[ad_1] On Thursday, Keefe, Bruyette & Woods maintained its Market Perform rating on JPMorgan shares, with a consistent price target

Estee Lauder hold stock rating maintained amid recovery concerns By Investing.com
- By aicren.com
- . May 16, 2024
[ad_1] On Thursday, Estee Lauder (NYSE:) maintained its hold stock rating by a market research firm due to concerns over

Morgan Stanley maintains Overweight on NICE, sees AI potential By Investing.com
- By aicren.com
- . May 16, 2024
[ad_1] On Thursday, Morgan Stanley reiterated its Overweight rating on shares of NICE Systems Ltd (NASDAQ:NICE), with a steady price

Morgan Stanley holds AIG at equal weight, target steady at $82 By Investing.com
- By aicren.com
- . May 16, 2024
[ad_1] On Thursday, Morgan Stanley maintained its Equalweight rating on American International Group (NYSE:) with a consistent price target of

Canada Goose’s stock soars as earnings beat offsets soft guidance
- By aicren.com
- . May 16, 2024
[ad_1] Canada Goose says it will focus on expanding its core product line beyond the parka, and change its approach

McDonald’s is bringing back its $5 value meal. Here are 10 other ways to save when dining out.
- By aicren.com
- . May 16, 2024
[ad_1] Follow these tips and you’ll reap the financial rewards. [ad_2] Source link

Individual investors made 30% of GameStop trades on Monday
- By aicren.com
- . May 16, 2024
[ad_1] As the stock prices of GameStop and AMC skyrocket, so does the number of people trading those shares. [ad_2]

Uber launches service that can help with eldercare
- By aicren.com
- . May 16, 2024
[ad_1] Transportation to medical appointments or medical errands can be arranged by app and paid for with health insurance [ad_2]

Cannabis stocks rise as U.S. moves to reclassify pot as less dangerous
- By aicren.com
- . May 16, 2024
[ad_1] Cannabis companies including Cresco Labs, Trulieve and Ayr Wellness post solid gains [ad_2] Source link

Biogen and Ionis Pharma shares slide as they end development of ALS treatment
- By aicren.com
- . May 16, 2024
[ad_1] The move comes after early-stage trial failed to result in a clear signal it slowed the disease process. [ad_2]